Orphan opportunity

Why KKR returned to co-lead Orphan play BridgeBio's $135M round

Private equity giant KKR returned to co-lead BridgeBio Pharma LLC's $135 million venture round, which could enable the Orphan play to double its pipeline in the next two years.

KKR co-led the Sept.

Read the full 335 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE